Atazanavir
- Generic Name
- Atazanavir
- Brand Names
- Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C38H52N6O7
- CAS Number
- 198904-31-3
- Unique Ingredient Identifier
- QZU4H47A3S
- Background
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the pa...
- Indication
Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at l...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed Conditions
- Conditions
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 42
- Registration Number
- NCT05236738
- Locations
- 🇺🇸
Local Institution - 0001, Miami, Florida, United States
Antiviral Agents Against COVID-19 Infection
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Hospital do Coracao
- Target Recruit Count
- 256
- Registration Number
- NCT04468087
- Locations
- 🇧🇷
Hospital do Coracao, Sao Paulo, SP, Brazil
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
- Conditions
- Interventions
- First Posted Date
- 2019-12-04
- Last Posted Date
- 2023-05-03
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT04184869
- Locations
- 🇺🇸
John Wayne Cancer Institute @ Providence Saint John's Health Center, Santa Monica, California, United States
Atazanavir and Endothelial Function in Older HIV Patients
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03019783
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen
- Conditions
- Interventions
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT02566707
- Locations
- 🇳🇱
St. Elisabeth, Tilburg, Netherlands
🇳🇱Rijstate, Arnhem, Netherlands
🇳🇱Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT02565888
- Locations
- 🇳🇱
CRCN, Radboud University Medical Center, Nijmegen, Netherlands
Taste Properties of Atazanavir and Cobicistat
- Conditions
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6
- Registration Number
- NCT02307656
- Locations
- 🇺🇸
Senopsys Llc, Woburn, Massachusetts, United States
Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2014-10-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 44
- Registration Number
- NCT02257008
Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT02253836
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
- First Posted Date
- 2014-04-17
- Last Posted Date
- 2019-04-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 11
- Registration Number
- NCT02116660
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.